AMOXICILLIN/CLAVULANATE POTASSIUM & AMOXICILLIN/CLAVULANIC ACID
AMOXICILLIN/CLAVULANATE
POTASSIUM
AMOXICILLIN/CLAVULANIC
ACID
Chemistry - A beta-lactamase inhibitor,
clavulanate potassium occurs as an off-white, crystalline powder that has a pKa
of 2.7 (as the acid) and is very soluble in water and slightly soluble in alcohol
at room temperatures. Although available in commercially available preparations
as the potassium salt, potency is expressed in terms of clavulanic acid.
Synonyms include: clavulanic acid and potassium clavulanate.
Storage/Stability/Compatibility - All
commercially available amoxicillin/potassium clavulanate products should be
stored at temperatures less than 24oC (75oF) in tight
containers. Potassium clavulanate is reportedly very susceptible to moisture
and should be protected from excessive humidity. After reconstitution, oral
suspensions are stable for 10 days when refrigerated. Unused portions should be
discarded after that time.
Pharmacology - Clavulanic acid has only weak
antibacterial activity when used alone and presently it is only available in
fixed-dose combination with either amoxicillin (oral) or ticarcillin (parenteral).
Clavulanic acid acts by competitively and irreversibly binding to beta-lactamases,
including types II, III, IV, and V, and penicillinases produced by
Staphylococcus. Staphylococci that are resistant to penicillinase-resistant
penicillins (e.g., oxacillin) are
considered to be resistant to amoxicillin/potassium clavulanate, although
susceptibility testing may indicate otherwise. Amoxicillin/potassium
clavulanate is usually ineffective against type I cephalosporinases. These plasmid-mediated
cephalosporinases are often produced by members of the family Enterobacteriaceae,
particularly Pseudomonas aeruginosa. When combined with amoxicillin, there is little if any synergistic
activity against organisms already susceptible to amoxicillin, but amoxicillin-resistant
strains (due to beta-lactamase inactivation) may be covered. When performing
Kirby-Bauer susceptibility testing, the Augmentin¨ (human-product trade name) disk is used. Because the
amoxicillin:clavulanic acid ratio of 2:1 in the susceptibility tests may not
correspond to in vivo drug levels,
susceptibility testing may not always accurately predict efficacy for this
combination.
Uses/Indications - Amoxicillin/potassium clavulanate
tablets and oral suspension products are approved for use in dogs and cats for
the treatment of urinary tract, and skin and soft tissue infections caused by
susceptible organisms. It is also indicated for canine periodontal disease due
to susceptible strains of bacteria.
Pharmacokinetics (specific) - There is no
evidence to suggest that the addition of clavulanic acid alters amoxicillin pharmacokinetics.
Clavulanate potassium is relatively stable in the presence of gastric acid and
is readily absorbed. In dogs, the absorption half-life is reportedly 0.39 hours
with peak levels occurring about 1 hour after dosing. Bioavailability data for
dogs or cats was not located. Clavulanic acid has an apparent volume of
distribution of 0.32 L/kg in dogs and is distributed (with amoxicillin) into
the lungs, pleural fluid and peritoneal fluid. Low concentrations of both drugs
are found in the saliva, sputum and CSF (uninflamed meninges). Higher
concentrations in the CSF are expected when meninges are inflamed, but it is
questionable whether therapeutic levels are attainable. Clavulanic acid is 13%
bound to proteins in dog serum. The drug readily crosses the placenta, but is
not believed to cause any teratogenic problems. Clavulanic acid and amoxicillin
are both found in milk in low concentrations. Clavulanic acid is apparently
extensively metabolized in the dog (and rats) primarily to 1-amino-4-hydroxybutan-2-one.
It is not known if this compound possess any beta-lactamase inhibiting activity.
The drug is also excreted unchanged in the urine via glomerular filtration. In
dogs, 34-52% of a dose is excreted in the urine as unchanged drug and
metabolites, 25-27% excreted in the feces, and 16-33% into respired air. Urine
levels of active drug are considered to be high, but may be only 1/5th of those
of amoxicillin.
Doses - All doses are for combined quantities of both
drugs (unless noted otherwise).
Dogs:
For susceptible infections:
a) 13.75 mg/kg PO bid; do not
exceed 30 days of therapy.
b) 10 - 20 mg/kg (amoxicillin) PO bid
c) 11 - 22 mg/kg PO q8-12h
d) 12.5 - 25 mg/kg PO q8-12h
Cats:
For
susceptible infections:
a)
62.5 mg PO bid; do not exceed 30 days of therapy.
b)
62.5 mg PO q8-12h
c)
11 - 22 mg/kg PO q8-12h
Birds:
For
susceptible infections:
a)
50 - 100 mg/kg PO q6-8h
Comments
Post a Comment